Spots Global Cancer Trial Database for cixutumumab
Every month we try and update this database with for cixutumumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | NCT01120236 | Prostate Adenoc... Recurrent Prost... Stage IV Prosta... | Bicalutamide Cixutumumab Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer | NCT00781911 | Carcinoma Neuroendocrine ... | Cixutumumab depot octreotid... | 18 Years - | Eli Lilly and Company | |
| Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | NCT01120236 | Prostate Adenoc... Recurrent Prost... Stage IV Prosta... | Bicalutamide Cixutumumab Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer | NCT00678769 | Malignant Neopl... | Cixutumumab Laboratory Biom... Pharmacological... Temsirolimus | 16 Years - | National Cancer Institute (NCI) | |
| Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma | NCT01016015 | Metastatic Oste... Recurrent Adult... Recurrent Osteo... Stage III Adult... Stage IV Adult ... | Cixutumumab Laboratory Biom... Temsirolimus | 16 Years - | National Cancer Institute (NCI) | |
| BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer | NCT01263782 | Lung Cancer | Carboplatin Pemetrexed Bevacizumab Cixutumumab | 18 Years - | M.D. Anderson Cancer Center | |
| Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | NCT00955305 | Large Cell Lung... Lung Adenocarci... Recurrent Non-S... Stage IV Non-Sm... Bronchioloalveo... | Bevacizumab Carboplatin Cixutumumab Paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| IMC-A12 in Treating Patients With Advanced Liver Cancer | NCT00639509 | Adult Primary H... Advanced Adult ... Localized Unres... Recurrent Adult... | cixutumumab computed tomogr... contrast-enhanc... | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00778167 | Recurrent Non-s... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-sm... | cixutumumab erlotinib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | NCT00684983 | HER2 Positive B... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Capecitabine Cixutumumab Lapatinib Ditos... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer | NCT00699491 | Male Breast Car... Recurrent Breas... Stage IV Breast... | Cixutumumab Laboratory Biom... Pharmacological... Temsirolimus | 18 Years - | National Cancer Institute (NCI) | |
| Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer | NCT00678769 | Malignant Neopl... | Cixutumumab Laboratory Biom... Pharmacological... Temsirolimus | 16 Years - | National Cancer Institute (NCI) | |
| Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment | NCT00880282 | Unspecified Chi... | cixutumumab temsirolimus pharmacological... laboratory biom... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| A Study in Non-Small Cell Lung Cancer | NCT01232452 | Non-Small-Cell ... | Pemetrexed Cisplatin Cixutumumab | 18 Years - | Eli Lilly and Company | |
| Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies | NCT01061749 | Adult Solid Neo... | Cixutumumab Laboratory Biom... Pharmacological... Selumetinib | 18 Years - | National Cancer Institute (NCI) | |
| Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | NCT01142388 | Metastatic Esop... Metastatic Esop... Metastatic Gast... Recurrent Esoph... Recurrent Esoph... Recurrent Esoph... Recurrent Gastr... Stage IV Esopha... | Cixutumumab Laboratory Biom... Paclitaxel Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer | NCT00684983 | HER2 Positive B... Recurrent Breas... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | Capecitabine Cixutumumab Lapatinib Ditos... Quality-of-Life... | 18 Years - | National Cancer Institute (NCI) | |
| Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer | NCT00678769 | Malignant Neopl... | Cixutumumab Laboratory Biom... Pharmacological... Temsirolimus | 16 Years - | National Cancer Institute (NCI) | |
| Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer | NCT01008566 | Adult Hepatocel... Advanced Adult ... Localized Non-R... Recurrent Adult... | Cixutumumab Laboratory Biom... Sorafenib Tosyl... | 19 Years - | National Cancer Institute (NCI) | |
| Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer | NCT00986674 | Recurrent Non-s... Stage IIIB Non-... Stage IV Non-sm... | cixutumumab carboplatin paclitaxel cetuximab | 18 Years - | National Cancer Institute (NCI) | |
| Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00778167 | Recurrent Non-s... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-sm... | cixutumumab erlotinib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | NCT00955305 | Large Cell Lung... Lung Adenocarci... Recurrent Non-S... Stage IV Non-Sm... Bronchioloalveo... | Bevacizumab Carboplatin Cixutumumab Paclitaxel | 18 Years - | National Cancer Institute (NCI) | |
| S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery | NCT00617708 | Stage IV Pancre... | cixutumumab erlotinib hydro... gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| A Study of IMC-A12 in Advanced Solid Tumors | NCT01007032 | Tumors | Cixutumumab | 20 Years - | Eli Lilly and Company | |
| Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | NCT00778167 | Recurrent Non-s... Stage IIIA Non-... Stage IIIB Non-... Stage IV Non-sm... | cixutumumab erlotinib hydro... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage | NCT00887159 | Extensive Stage... Recurrent Small... | Cisplatin Cixutumumab Etoposide Laboratory Biom... Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies | NCT01061749 | Adult Solid Neo... | Cixutumumab Laboratory Biom... Pharmacological... Selumetinib | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
